Updated on 10 June 2013
The benefits of our plastic needles are their safety features, ease-of-recyclability and a more cost efficient lifecycle (from production to disposal), as compared to steel. Furthermore, it does not interfere with medical imaging technologies and our range can be customized for both human and animal use, as well as medical and non-medical applications.
What is your go-to-market strategy?
We brought this technology and product to market, culminating in FDA registration, in a speedy cycle of 15 months. One of the roles of the CoreIT Technology and the SoloFlow Reconstitution Needle is to demonstrate to the market that a non-injection plastic needle can perform well against its steel counterpart and offer benefits of cost competitiveness, recyclability and safer practice.
We have continued to discuss our technologies and benefits with prospective organizations globally such as pharmaceutical companies looking for drug delivery solutions. Our technology is the differentiator in this crowded market.
What is the revenue forecast for 2013?
Telezon is at a very exciting time at this juncture. It is currently seeking investment to accelerate commercialization of its products and technologies in the global market. In addition, this investment will also support our existing commercial agreements, two of which are with Indian companies. So, it will be safe to say that we have a positive financial outlook for 2013.
Which geographies are you focusing on?
Our portfolio is relevant to markets globally. India is our first market. We are currently supplying the SoloFlow Needle technology to the Serum Institute of India (SII). Growing healthcare industry and large market in India, provides us with substantial opportunity. Discussions with Indian companies and healthcare providers have been positive and they have demonstrated considerable interest. We also have a commercial agreement with India's Hindustan Syringes and Medical Devices (HMD), the manufacturers of Dispovan syringes.